Linked Data API

Show Search Form

Search Results

1186534
star this property registered interest false more like this
star this property date less than 2020-03-19more like thismore than 2020-03-19
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading National Institute for Health and Care Excellence remove filter
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, if he will support the National Institute for Health and Care Excellence to undertake its methods and processes in a way that (a) enables the attractiveness of the UK as a place to conduct clinical trials or supply human medicines and (b) enables that organisation to fulfil its statutory duty to promote innovation. more like this
star this property tabling member constituency Reigate more like this
star this property tabling member printed
Crispin Blunt more like this
star this property type
WrittenParliamentaryQuestion
star this property uin 32039 remove filter
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2020-05-29more like thismore than 2020-05-29
star this property answer text <p>The National Institute for Health and Care Excellence (NICE) is reviewing its methods for the development of technology appraisal and highly specialised technology recommendations in line with the commitment in the 2019 voluntary scheme for branded medicines pricing and access. The scheme also states the Government’s expectations for the review as follows: ‘“The Department expects that any future changes to NICE methods and processes would respond to the new types of innovation coming to the market, be consistent with improving the health gain achieved by spending on new innovative medicines, and support faster adoption of the most clinically and cost effective medicines.”’</p><p> </p><p><strong> </strong></p><p><strong> </strong></p> more like this
star this property answering member constituency Bury St Edmunds more like this
star this property answering member printed Jo Churchill more like this
star this property grouped question UIN 32038 more like this
star this property question first answered
less than 2020-05-29T16:49:06.817Zmore like thismore than 2020-05-29T16:49:06.817Z
star this property answering member
4380
star this property label Biography information for Jo Churchill more like this
star this property tabling member
104
star this property label Biography information for Crispin Blunt more like this